Biorestorative Therapies (BRTX)
(Delayed Data from NSDQ)
$1.73 USD
+0.04 (2.37%)
Updated Oct 15, 2024 03:46 PM ET
After-Market: $1.73 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.73 USD
+0.04 (2.37%)
Updated Oct 15, 2024 03:46 PM ET
After-Market: $1.73 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Zacks News
Biorestorative Therapies, Inc. (BRTX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Biorestorative Therapies (BRTX) delivered earnings and revenue surprises of 10.71% and 196.67%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
TScan Therapeutics (TCRX) delivered earnings and revenue surprises of 6.67% and 65.31%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Revance Therapeutics, Inc. (RVNC) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Revance Therapeutics (RVNC) delivered earnings and revenue surprises of 25% and 1.10%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Krystal Biotech, Inc. (KRYS) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Krystal Biotech (KRYS) delivered earnings and revenue surprises of 72% and 18.66%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Biorestorative Therapies (BRTX) delivered earnings and revenue surprises of -3.92% and 16.67%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
QIAGEN (QGEN) Extends the AI-Powered QCI Interpret Software
by Zacks Equity Research
QIAGEN's (QGEN) NGS interpretation software, QCI Interpret, now covers the whole exome due to additional AI capabilities.
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Y-mAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of 41.67% and 8.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Mirati (MRTX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Mirati (MRTX) delivered earnings and revenue surprises of 5.88% and 1.63%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?